Strategies to combat coccidioidomycosis: Are we making any progress?

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Coccidioidomycosis is caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. One of the endemic mycoses, this organism has been found solely in the semiarid to arid life zones of the southwestern United States, Mexico, and parts of Central America and South America. Clinical manifestations of disease vary greatly between patients and are largely dependent upon both the extent of exposure and the immune status of the host. The incidence of coccidioidomycosis continues to rise within the United States. Primary coccidioidal pneumonia accounts for close to 25% of all community-acquired pneumonia within endemic regions, reflecting the substantial burden of disease and health care costs associated with this infection. Although most patients with coccidioidomycosis resolve their initial infection without long-term complications, a minority of patients develop complications of disease ranging from asymptomatic pulmonary nodules to life-threatening disease such as meningitis. This review focuses on the epidemiology, clinical manifestations, spectrum of disease, and treatment options currently available for coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalCurrent Fungal Infection Reports
Issue number4
StatePublished - 2011


  • Antifungal agents
  • Coccidioidal pneumonia
  • Coccidioides
  • Coccidioidomycosis
  • Diagnosis
  • Epidemiology
  • Immunogenetics
  • Prophylaxis
  • Pulmonary complications
  • Risk factors
  • Treatment
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Strategies to combat coccidioidomycosis: Are we making any progress?'. Together they form a unique fingerprint.

Cite this